"The Company expects to receive formal written communication with the additional information from the FDA and plans to work with the FDA in an effort to resolve its questions as promptly as possible," Ocugen said in its recent release.
COVAXIN (BBV152) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. With more than 100 million doses having been administered to adults outside the U.S., COVAXIN is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 other countries.
The World Health Organization (WHO) recently added COVAXIN to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN. The trade name COVAXIN has not been evaluated by the FDA.
As recently published in, The Lancet, COVAXIN (BBV152) demonstrated 77.8% overall efficacy, 63.6% efficacy against asymptomatic disease and 65.2% efficacy against the Delta variant in the Phase 3 clinical trial of nearly 25,800 participants. The trial was conducted in India and sponsored by Bharat Biotech.
Read also: Ocugen seeks USFDA nod for EUA of Covaxin for paediatric use
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.